

**Draft Guidance on Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate**

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

**Active ingredient:** Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate

**Form/Route:** Tablets/Oral

**Recommended studies:** 1 study

Type of study: Fasting

Design: Single-dose, two-treatment, two-period crossover *in-vivo*

Strength: 600 mg/200 mg/300 mg

Subjects: Normal healthy males and females, general population.

Additional Comments: Females should not be pregnant or lactating, and if applicable, should practice abstention or contraception during the study.

---

**Analytes to measure (in appropriate biological fluid):** Efavirenz, emtricitabine, and tenofovir in plasma.

**Bioequivalence based on (90% CI):** Efavirenz, emtricitabine, and tenofovir

**Waiver request of *in-vivo* testing:** Not Applicable

**Dissolution test method and sampling times:**

Please note that a **Dissolution Methods Database** is available to the public at the OGD website at <http://www.fda.gov/cder/ogd/index.htm>. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.